Lead Product(s) : INV-001
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Innovo Therapeutics Announces Positive Phase 2 Results for Post-Thyroidectomy Scars
Details : INV-001 inhibits HSP47, a key protein in collagen formation, transport, and extracellular secretion, thereby preventing and treating post-surgical and trauma-induced scars.
Product Name : INV-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 20, 2024
Lead Product(s) : INV-001
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Taurodeoxycholic Acid
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Shaperon Enrolls First Patient in Phase 2 U.S. Trial for Atopic Dermatitis Therapy 'Nugel'
Details : NuGel® is a gel type atopic dermatitis drug candidate, inhibiting NLRP3 inflammasome through GPCR19-P2X7 modulation. Its active pharmaceutical ingredient called HY209.
Product Name : Nugel
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 18, 2024
Lead Product(s) : Taurodeoxycholic Acid
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OLX10010
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OLX10010 is an asymmetric siRNA duplex with a cell-penetrating moiety attached to the 3’ of sense strand (cell-penetrating asymmetric siRNA, i.e. cp-asiRNA), targeting human connective tissue growth factor, which is a key factor in the development of h...
Product Name : OLX101A
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
April 28, 2023
Lead Product(s) : OLX10010
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OLX10010
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OLX10010 (compound name of OLX101A), a drug that targets connective tissue growth factor, is in phase 2 development as a treatment for hypertrophic scar.
Product Name : OLX101A
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
July 06, 2022
Lead Product(s) : OLX10010
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OLX10010
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : KB investment
Deal Size : $45.0 million
Deal Type : Financing
Details : The capital will be used to finance R&D activities. The Company’s dry and wet AMD (OLX301A/OLX10010) and androgenic alopecia (OLX104C) programs are also planned to be entered into clinical trials, followed by HBV (OLX703A) and nonalcoholic steatohepati...
Product Name : OLX101A
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
May 27, 2022
Lead Product(s) : OLX10010
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : KB investment
Deal Size : $45.0 million
Deal Type : Financing
Lead Product(s) : OLX10010
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : $37.2 million
Deal Type : Financing
Details : Capital will fund construction of RNA synthesis GMP facility in San Diego to advance the company’s core pipeline, including OLX101A for hypertrophic scars, OLX301A for age-related macular degeneration and OLX301D for subretinal fibrosis.
Product Name : OLX101A
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
January 12, 2020
Lead Product(s) : OLX10010
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : $37.2 million
Deal Type : Financing